The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

Europe's largest "green" methanol plant opened in Denmark on Tuesday, boosting the continent's emissions reduction efforts -- ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Elon Musk is President Trump’s “seriously overweight” friend who takes “the fat shot,” according to the Tesla CEO’s own artificial intelligence bot. Trump was discussing plans to lower medication ...

ParticipACTION will kick off its search for Canada's Most Active Community with the ParticipACTION Community Challenge ...

To sharpen focus on the global commercialization of strategic products and the external partnership model, LEO Pharma makes ...

Our writer shines a light on a trio of outperforming growth firms in his Stocks and Shares ISA portfolio. They're easily offsetting a couple of duds!

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...